- Home
- ESLA vs SPRO Comparison
ESLA vs SPRO Comparison
Compare ESLA & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESLA
- SPRO
- Stock Information
- Founded
- ESLA 2021
- SPRO 2013
- Country
- ESLA United States
- SPRO United States
- Employees
- ESLA N/A
- SPRO N/A
- Industry
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- ESLA Health Care
- SPRO Health Care
- Exchange
- ESLA Nasdaq
- SPRO Nasdaq
- Market Cap
- ESLA 35.5M
- SPRO 33.0M
- IPO Year
- ESLA N/A
- SPRO 2017
- Fundamental
- Price
- ESLA $1.07
- SPRO $2.50
- Analyst Decision
- ESLA Strong Buy
- SPRO Buy
- Analyst Count
- ESLA 1
- SPRO 4
- Target Price
- ESLA $16.00
- SPRO $5.00
- AVG Volume (30 Days)
- ESLA 518.6K
- SPRO 11.5M
- Earning Date
- ESLA 06-17-2025
- SPRO 08-04-2025
- Dividend Yield
- ESLA N/A
- SPRO N/A
- EPS Growth
- ESLA N/A
- SPRO N/A
- EPS
- ESLA N/A
- SPRO N/A
- Revenue
- ESLA N/A
- SPRO $44,584,000.00
- Revenue This Year
- ESLA $101.09
- SPRO N/A
- Revenue Next Year
- ESLA N/A
- SPRO N/A
- P/E Ratio
- ESLA N/A
- SPRO N/A
- Revenue Growth
- ESLA N/A
- SPRO N/A
- 52 Week Low
- ESLA $0.63
- SPRO $0.51
- 52 Week High
- ESLA $3.23
- SPRO $2.95
- Technical
- Relative Strength Index (RSI)
- ESLA 55.18
- SPRO 77.34
- Support Level
- ESLA $0.78
- SPRO $2.47
- Resistance Level
- ESLA $1.18
- SPRO $2.90
- Average True Range (ATR)
- ESLA 0.10
- SPRO 0.23
- MACD
- ESLA 0.00
- SPRO 0.16
- Stochastic Oscillator
- ESLA 71.28
- SPRO 80.47
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.